Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030712 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
A Phase 1 study of Metastatic Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 5
- Study locations
NCT07030712 is a Phase 1 study of Metastatic Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 67 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT07030712, a Phase 1 study of Metastatic Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 5
- Study locations
Study Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Conditions Studied
Interventions
- DRUG MK-8294
Study Locations (5)
Other
- Rambam Health Care Campus ( Site 0201) - Haifa
- Sheba Medical Center ( Site 0200) - Ramat Gan
Illinois
- Northwestern University ( Site 0101) - Chicago
Gelderland
- Radboudumc ( Site 0301) - Nijmegen
North Holland
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300) - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2025-07-23 |
| Est. Completion | 2027-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07030712
The ClinicalTrials.gov registry entry for NCT07030712 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which MK-8294 is the first listed.
NCT07030712 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Illinois, Gelderland.
Frequently Asked Questions
What is clinical trial NCT07030712 about?
NCT07030712 is a clinical study titled "A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)". MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
What is the current status of trial NCT07030712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-07-23. Estimated completion is 2027-08-23.
What conditions does trial NCT07030712 study?
This clinical trial studies the following conditions: Metastatic Neoplasm.
What interventions are being tested in trial NCT07030712?
The interventions under investigation include: MK-8294 (DRUG).
Who is sponsoring clinical trial NCT07030712?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030712 being conducted?
This trial has 5 study locations across Illinois, Gelderland, North Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.